| Today’s Big NewsFeb 5, 2025 |
|
Wednesday, February 12, 2025 | 10am ET / 7am PT If you are a company developing advanced therapies, don’t miss this webinar to learn about packaging innovations and aseptic filling solutions that meet the demands of emerging therapies and ensure product integrity, safety and efficiency. Register now. 
|
|
| By Nick Paul Taylor Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. Months after sharing obesity data that left investors underwhelmed, the Danish drugmaker has reported the failure of a midphase diabetic kidney disease trial of the molecule. |
|
|
|
By Gabrielle Masson Precision medicines biotech Frontier Medicines is leaving behind an unknown number of staffers as it refocuses resources to optimize operations. |
By Darren Incorvaia Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial on a clinical hold, the biotech announced Feb. 4. Amgen didn’t disclose the reason for the hold. |
By James Waldron GSK is prioritizing development of its hepatitis B treatment bepirovirsen, even as the pharma ends work on another potential functional cure for the infectious disease. |
|
Thursday, February 20, 2025 | 1pm ET / 10am PT ALS remains one of the most complex neurological diseases to understand and treat. Join industry experts to learn about the latest advancements in ALS research, with exclusive insights into the latest scientific progress shaping the future of ALS therapies. Register now. 
|
|
By James Waldron Qlaris Bio hit the primary endpoints in two mid-stage trials that both spanned primary open-angle glaucoma and ocular hypertension. |
By Gabrielle Masson Valerio Therapeutics is ending all clinical trials, including an ongoing phase 1/2 study for its investigational “DNA decoy” candidate designed to treat recurrent solid tumor cancers. |
By Gabrielle Masson,Darren Incorvaia As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team. |
By Darren Incorvaia Canadian CRO Innovaderm Research is looking to grow with new CEO Jeff Smith leading the way. Smith is taking over the top spot from founder Robert Bissonnette, M.D., who will stay on as executive chairman. |
By Kevin Dunleavy Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened its label as a treatment for diabetic macular edema, which is the leading cause of diabetes-related blindness. |
By Noah Tong Government unions and cybersecurity experts are disturbed by Elon Musk's newfound access to personal information and the country's payment infrastructure, which coordinates funds for government health programs like Medicare and Medicaid. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we zoom in on a Fierce JPM Week panel of industry experts discussing what it will take for biotechs to pull off a successful IPO in 2025. |
|
|---|
|
|
|
Wednesday, February 19, 2025 | 11am ET / 8am PT This webinar takes a deep dive into effective formulation strategies to overcome current solubility and bioavailability hurdles. Join us to explore the latest advancements in bioavailability enhancement technologies and critical factors for selecting the right formulation approach. Register now. 
|
|
Whitepaper This paper reviews key developments in the oncology market during 2024 and outlines what they mean for the future. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
